Trial Profile
A Study of Enfortumab Vedotin (ASG-22CE) as Monotherapy or in Combination With Other Anticancer Therapies for the Treatment of Urothelial Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Enfortumab vedotin (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Bladder cancer; Carcinoma; Pelvic cancer; Renal cancer; Squamous cell cancer; Ureteral neoplasms; Urethral cancer; Urogenital cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms EV-103; KEYNOTE-869
- Sponsors Astellas Pharma Global Development; Seagen
- 12 Jan 2024 Results of Exploratory patient-reported outcomes , published in the Journal of Clinical Oncology
- 01 Nov 2023 According to Seagen media release, data from this trial presented at the European Society for Medical Oncology (ESMO) Congress 2023
- 24 Oct 2023 Results (n=52) from cohort L of the study, presented at the 48th European Society for Medical Oncology Congress.